Neurotrophic factors as a protective strategy in Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 754-763

  Diógenes, Maria José ^a   Outeiro, Tiago Fleming ^b,c  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Brain derived neurotrophic factor; Glial cell linederived neurotrophic factor.e Rating Scale; Neurodegeneration; Neurotrophins; Parkinson's disease; Protein misfolding

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ARTEMIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; NEURTURIN; PERSEPHIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

AKINESIA; ANOREXIA; ARTICLE; BRADYKINESIA; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DYSARTHRIA; DYSKINESIA; DYSPHAGIA; FRONTOTEMPORAL DEMENTIA; HUMAN; HYPERSALIVATION; HYPONATREMIA; LOW DRUG DOSE; NAUSEA; NONHUMAN; PARESTHESIA; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; RIGIDITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANTIA NIGRA; TACHYPHYLAXIS; TREMOR; URINARY DYSFUNCTION; WEIGHT REDUCTION;

EID: 78649251977     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237449     Document Type: Article

References (82)

1. Forman, M.S.; Trojanowski, J.Q.; Lee, V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med., 2004, 10(10), 1055-1063.
2. Thomas, P.J.; Qu, B.H.; Pedersen, P.L. Defective protein folding as a basis of human disease. Trends Biochem. Sci., 1995, 20(11), 456-459.
3. Muchowski, P.J. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron, 2002, 35(1), 9-12.
4. Soto, C.; Estrada, L.; Castilla, J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem. Sci., 2006, 31(3), 150-155.
5. Ross, C.A.; Poirier, M.A. Protein aggregation and neurodegenerative disease. Nat. Med., 2004, 10(Suppl), S10-S17.
6. Caughey, B. Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci., 2003, 26, 267-298.
7. Chiti, F.; Dobson, C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366.
8. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
9. Dobson, C.M. Protein folding and misfolding. Nature, 2003, 426(6968), 884-890.
10. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci., 2001, 2(7), 492-501.
11. Irizarry, M.C.; Growdon, W.; Gomez-Isla, T.; Newell, K.; George, J.M.; Clayton, D.F.; Hyman, B.T. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol., 1998, 57(4), 334-337.
12. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
13. Outeiro, T.F.; Klucken, J.; Strathearn, K.E.; Liu, F.; Nguyen, P.; Rochet, J.C.; Hyman, B.T.; McLean, P.J. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem. Biophys. Res. Commun., 2006, 351(3), 631-638.
14. Ding, T.T.; Lee, S.J.; Rochet, J.C.; Lansbury, P.T., Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry, 2002, 41(32), 10209-10217.
15. Outeiro, T.F.; Putcha, P.; Tetzlaff, J.E.; Spoelgen, R.; Koker, M.; Carvalho, F.; Hyman, B.T.; McLean, P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE, 2008, 3(4), e1867.
16. Klucken, J.; Outeiro, T.F.; Nguyen, P.; McLean, P.J.; Hyman, B.T. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J., 2006, 20(12), 2050-2057.
17. Gasser, T. Update on the genetics of Parkinson's disease. Mov. Disord., 2007, 22(Suppl 17), S343-S350.
18. Albin, R.L.; Aldridge, J.W.; Young, A.B.; Gilman, S. Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res., 1989, 491(1), 185-188.
19. DeLong, M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci., 1990, 13(7), 281-285.
20. Obeso, J.A.; Rodríguez-Oroz, M.C.; Rodríguez, M.; Lanciego, J.L.; Artieda, J.; Gonzalo, N.; Olanow, C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci., 2000, 23(10 Suppl), S8-S19.
21. Galvan, A. Wichmann, T. Pathophysiology of parkinsonism. Clin. Neurophysiol., 2008, 119(7), 1459-1474.
22. Howells, D.W.; Porritt, M.J.; Wong, J.Y.; Batchelor, P.E.; Kalnins, R.; Hughes, A.J.; Donnan, G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol., 2000, 166(1), 127-135.
23. Chauhan, N.B.; Siegel, G.J.; Lee, J.M. Depletion of glial cell linederived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat., 2001, 21(4), 277-288.
24. Mogi, M.; Togari, A.; Kondo, T.; Mizuno, Y.; Komure, O.; Kuno, S.; Ichinose, H.; Nagatsu, T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett., 1999, 270(1), 45-48.
25. Cohen, S.; Levi-Montalcini, R.; Hamburger, V. A Nerve Growth-Stimulating Factor Isolated from Sarcom as 37 and 180. Proc. Natl. Acad. Sci. USA, 1954, 40(10), 1014-1018.
26. Kaplan, D.R.; Martin-Zanca, D.; Parada, L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk protooncogene product induced by NGF. Nature, 1991, 350(6314), 158-160.
27. Klein, R.; Jing, S.Q.; Nanduri, V.; O'Rourke, E.; Barbacid, M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell, 1991, 65(1), 189-197.
28. Bibel, M.; Barde, Y.A. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev., 2000, 14(23), 2919-2937.
29. Segal, R.A.; Greenberg, M.E. Intracellular signaling pathways activated by neurotrophic factors. Annu. Rev. Neurosci., 1996, 19, 463-489.
30. Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 1993, 260(5111), 1130-1132.
31. Sariola, H.; Saarma, M. Novel functions and signalling pathways for GDNF. J. Cell Sci., 2003, 116(Pt 19), 3855-3862.
32. Ledda, F.; Paratcha, G.; Ibanez, C.F. Target-derived GFRalpha1 as an attractive guidance signal for developing sensory and sympathetic axons via activation of Cdk5. Neuron, 2002, 36(3), 387-401.
33. Paratcha, G.; Ledda, F.; Baars, L.; Coulpier, M.; Besset, V.; Anders, J.; Scott, R.; Ibáñez, C.F. Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron, 2001, 29(1), 171-184.
34. Paratcha, G.; Ledda, F.; Ibanez, C.F. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell, 2003, 113(7), 867-879.
35. Seroogy, K.B.; Lundgren, K.H.; Tran, T.M.; Guthrie, K.M.; Isackson, P.J.; Gall, C.M. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J. Comp. Neurol., 1994, 342(3), 321-334.
36. Zhang, H.T.; Li, L.Y.; Zou, X.L.; Song, X.B.; Hu, Y.L.; Feng, Z.T.; Wang, T.T. Immunohistochemical distribution of NGF, BDNF, NT-3, and NT-4 in adult rhesus monkey brains. J. Histochem. Cytochem., 2007, 55(1), 1-19.
37. Baquet, Z.C.; Bickford, P.C.; Jones, K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci., 2005, 25(26), 6251-6259.
38. Momose, Y.; Murata, M.; Kobayashi, K.; Tachikawa, M.; Nakabayashi, Y.; Kanazawa, I.; Toda, T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol., 2002, 51(1), 133-136.
39. Karamohamed, S.; Latourelle, J.C.; Racette, B.A.; Perlmutter, J.S.; Wooten, G.F.; Lew, M.; Klein, C.; Shill, H.; Golbe, L.I.; Mark, M.H.; Guttman, M.; Nicholson, G.; Wilk, J.B.; Saint-Hilaire, M.; DeStefano, A.L.; Prakash, R.; Tobin, S.; Williamson, J.; Suchowersky, O.; Labell, N.; Growdon, B.N.; Singer, C.; Watts, R.; Goldwurm, S.; Pezzoli, G.; Baker, K.B.; Giroux, M.L.; Pramstaller, P.P.; Burn, D.J.; Chinnery, P.; Sherman, S.; Vieregge, P.; Litvan, I.; Gusella, J.F.; Myers, R.H.; Parsian, A. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology, 2005, 65(11), 1823-1825.
40. Parain, K.; Murer, M.G.; Yan, Q.; Faucheux, B.; Agid, Y.; Hirsch, E.; Raisman-Vozari, R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport, 1999, 10(3), 557-561.
41. Ryoo, H.L.; Pierrotti, D.; Joyce, J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord., 1998, 13(5), 788-797.
42. Grondin, R.; Zhang, Z.; Yi, A.; Cass, W.A.; Maswood, N.; Andersen, A.H.; Elsberry, D.D.; Klein, M.C.; Gerhardt, G.A.; Gash, D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain, 2002, 125(Pt 10), 2191-2201.
43. von Bohlen und Halbach, O.; Minichiello, L.; Unsicker, K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J., 2005, 19(12), 1740-1742.
44. Okazawa, H.; Murata, M.; Watanabe, M.; Kamei, M.; Kanazawa, I. Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett., 1992, 313(2), 138-142.
45. Zhang, X.; Andren, P.E.; Svenningsson, P. Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res., 2006, 1095(1), 207-210.
46. Gomes, C.A.; Simões, P.F.; Canas, P.M.; Quiroz, C.; Sebastião, A.M.; Ferré, S.; Cunha, R.A.; Ribeiro, J.A. GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors. J. Neurochem., 2009, 108(5), 1208-1219.
47. Mogi, M.; Togari, A.; Kondo, T.; Mizuno, Y.; Kogure, O.; Kuno, S.; Ichinose, H.; Nagatsu, T. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci. Lett., 2001, 300(3), 179-181.
48. Bordet, R.; Ridray, S.; Carboni, S.; Diaz, J.; Sokoloff, P.; Schwartz, J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA, 1997, 94(7), 3363-3367.
49. Backman, C.M.; Shan, L.; Zhang, Y.J.; Hoffer, B.J.; Leonard, S.; Troncoso, J.C.; Vonsatel, P.; Tomac, A.C. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol. Cell. Endocrinol., 2006, 252(1-2), 160-166.
50. Tsukahara, T.; Takeda, M.; Shimohama, S.; Ohara, O.; Hashimoto, N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery, 1995, 37(4), 733-739.
51. Yoshimoto, Y.; Lin, Q.; Collier, T.J.; Frim, D.M.; Breakefield, X.O.; Bohn, M.C. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res., 1995, 691(1-2), 25-36.
52. Levivier, M.; Przedborski, S.; Bencsics, C.; Kang, U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brainderived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci., 1995, 15(12), 7810-7820.
53. Fontinha, B.M.; Diógenes, M.J.; Ribeiro, J.A.; Sebastião, A.M. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology, 2008, 54(6), 924-933.
54. Frim, D.M.; Uhler, T.A.; Galpern, W.R.; Beal, M.F.; Breakefield, X.O.; Isacson, O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. USA, 1994, 91(11), 5104-5108.
55. Sadan, O.; Bahat-Stromza, M.; Barhum, Y.; Levy, Y.S.; Pisnevsky, A.; Peretz, H.; Ilan, A.B.; Bulvik, S.; Shemesh, N.; Krepel, D.; Cohen, Y.; Melamed, E.; Offen, D. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev., 2009, 18(8), 1179-1190.
56. Klein, R.L.; Lewis, M.H.; Muzyczka, N.; Meyer, E.M. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res., 1999, 847(2), 314-320.
57. Sun, M.; Kong, L.; Wang, X.; Lu, X.G.; Gao, Q.; Geller, A.I. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res., 2005, 1052(2), 119-129.
58. Tomac, A.; Lindqvist, E.; Lin, L.F.; Ogren, S.O.; Young, D.; Hoffer, B.J.; Olson, L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature, 1995, 373(6512), 335-339.
59. Sautter, J.; Tseng, J.L.; Braguglia, D.; Aebischer, P.; Spenger, C.; Seiler, R.W.; Widmer, H.R.; Zurn, A.D. Implants of polymerencapsulated genetically modified cells releasing glial cell linederived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol., 1998, 149(1), 230-236.
60. Galpern, W.R.; Frim, D.M.; Tatter, S.B.; Altar, C.A.; Beal, M.F.; Isacson, O. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant., 1996; 5(2), 225-232.
61. Granholm, A.C.; Reylandm M, Albeck, D.; Sanders, L.; Gerhardt, G.; Hoernig, G.; Shen, L.; Westphal, H.; Hoffer, B. Glial cell linederived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J. Neurosci., 2000, 20(9), 3182-3190.
62. Nutt, J.G.; Burchiel, K.J.; Comella, C.L.; Jankovic, J.; Lang, A.E.; Laws, E.R., Jr.; Lozano, A.M.; Penn, R.D.; Simpson, R.K., Jr.; Stacy, M.; Wooten, G.F.; ICV GDNF Study Group. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 2003, 60(1), 69-73.
63. Gash, D.M.; Zhang, Z.; Ovadia, A.; Cass, W.A.; Yi, A.; Simmerman, L.; Russell, D.; Martin, D.; Lapchak, P.A.; Collins, F.; Hoffer, B.J.; Gerhardt, G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature, 1996, 380(6571), 252-255.
64. Patel, N.K.; Bunnage, M.; Plaha, P.; Svendsen, C.N.; Heywood, P.; Gill, S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol., 2005, 57(2), 298-302.
65. Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A.; Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P.; Brodsky, M.A.; Burchiel, K.; Kelly, P.; Dalvi, A.; Scott, B.; Stacy, M.; Turner, D.; Wooten, V.G.; Elias, W.J.; Laws, E.R.; Dhawan, V.; Stoessl, A.J.; Matcham, J.; Coffey, R.J.; Traub, M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 2006, 59(3), 459-466.
66. Slevin, J.T.; Gerhardt, G.A.; Smith, C.D.; Gash, D.M.; Kryscio, R.; Young, B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg., 2005, 102(2), 216-222.
67. Slevin, J.T.; Gash, D.M.; Smith, C.D.; Gerhardt, G.A.; Kryscio, R.; Chebrolu, H.; Walton, A.; Wagner, R.; Young, A.B. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg. Focus, 2006, 20(5), E1.
68. Lee, F.S.; Chao, M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA, 2001; 98(6), 3555-3560.
69. Diaz-Cabiale, Z.; Hurd, Y.; Guidolin, D.; Finnman, U.B.; Zoli, M.; Agnati, L.F.; Vanderhaeghen, J.J.; Fuxe, K.; Ferré, S. Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport, 2001, 12(9), 1831-1834.
70. Diogenes, M.J.; Fernandes, C.C.; Sebastião, A.M.; Ribeiro, J.A. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci., 2004, 24(12), 2905-2913.
71. Tebano, M.T.; Martire, A.; Potenza, R.L.; Grò, C.; Pepponi, R.; Armida, M.; Domenici, M.R.; Schwarzschild, M.A.; Chen, J.F.; Popoli, P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J. Neurochem., 2008, 104(1), 279-286.
72. Ferre, S.; Rimondini, R.; Popoli, P.; Reggio, R.; Pèzzola, A.; Hansson, A.C.; Andersson, A.; Fuxe, K. Stimulation of adenosine A1 receptors attenuates dopamine D1 receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels in the dopaminedenervated striatum and dopamine D1 receptor-mediated turning behaviour. Eur. J. Neurosci., 1999, 11(11), 3884-3892.
73. Diogenes, M.J.; Assaife-Lopes, N.; Pinto-Duarte, A.; Ribeiro, J.A.; Sebastião, A.M. Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus, 2007, 17(7), 577-585.
74. Pousinha, P.A.; Diogenes, M.J.; Ribeiro, J.A.; Sebastião, AM. Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A2A receptors. Neurosci. Lett., 2006, 404(1-2), 143-147.
75. Wiese, S.; Jablonka, S.; Holtmann, B.; Orel, N.; Rajagopal, R.; Chao, M.V.; Sendtner, M. Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc. Natl. Acad. Sci. USA, 2007, 104(43), 17210-17215.
76. Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9(5), 589-595.
77. Sebastiao, A.M.; Ribeiro, J.A. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br. J. Pharmacol., 2009, 158(1), 15-22.
78. Golder, F.J.; Ranganathan, L.; Satriotomo, I.; Hoffman, M.; Lovett-Barr, M.R.; Watters, J.J.; Baker-Herman, T.L.; Mitchell, G.S. Spinal adenosine A2a receptor activation elicits long-lasting phrenic motor facilitation. J. Neurosci., 2008, 28(9), 2033-2042.
79. Gomes, C.A.; Vaz S.H.; Ribeiro, J.A.; Sebastião, A.M. Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptordependent manner. Brain Res., 2006, 1113(1), 129-136.
80. Fernandes, C.C.; Pinto-Duarte, A.; Ribeiro, J.A.; Sebastião, A.M. Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. J. Neurosci., 2008, 28(21), 5611-5618.
81. Wardas, J.; Konieczny, J.; Lorenc-Koci, E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse, 2001, 41(2), 160-171.
82. Morelli, M.; Di Paolo, T.; Wardas, J.; Calon, F.; Xiao, D.; Schwarzschild, M.A. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol., 2007, 83(5), 293-309.